Neumedicines Inc (AKA: Neumedicines LLC) Profile last edited on: 6/17/21
CAGE: 47KZ7
UEI:
Business Identifier: Protein therapies for the treatment of hematopoietic deficiencies and cancer, 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
133 North Altadena Drive Suite 310
Pasadena, CA 91107
Pasadena, CA 91107
| (626) 844-3800 |
| info@neumedicines.com |
| www.neumedicines.com |
Location: Single
Congr. District: 27
County: Los Angeles
Congr. District: 27
County: Los Angeles
Public Profile
Neumedicines Inc. is an emerging therapeutic biotechnology company focused on developing and commercializing innovative and proprietary products and approaches that address unmet clinical and societal needs in the areas of oncology, hematology, and immunology. The firm's lead product candidate is recombinant human interleukin-12 (rHuIL-12), a heterodimeric glycoprotein and cytokine being developed under the trade name HemaMax⢠for various clinical indications, including hematopoietic syndrome of acute radiation syndrome (HSARS), skin cancers and other solid tumors, and blood disorders and malignancie
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
10-14Revenue Range
1M-1.5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
5-9Awards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2016 | 2 | NIH | $1,505,508 | |
| Project Title: A Phase I Study of rHuIL-12 as an Immunotherapy and Radiomitigator for CTCL Patients Receiving Radiotherapy | ||||
| 2008 | 2 | NIH | $1,321,039 | |
| Project Title: Retroviral Vectors for Safe and Efficacious Gene Therapy | ||||
| 2007 | 1 | NIH | $197,568 | |
| Project Title: IL-12-Faciliated Hematopoietic Recovery Following Myeloablative Therapy | ||||
| 2006 | 2 | NIH | $849,998 | |
| Project Title: Uses of IL-12 as a Hematological Adjuvant Cancer Therapy | ||||
Key People / Management
Lena A Basile -- President & Founder
W French Anderson
Dan Douer
Tim Gallagher -- Director of Pharmacology and Proteomics
David Morash -- Chief Financial Officer
Raphael Nir -- Director of Process Development
Yi Zhao
W French Anderson
Dan Douer
Tim Gallagher -- Director of Pharmacology and Proteomics
David Morash -- Chief Financial Officer
Raphael Nir -- Director of Process Development
Yi Zhao
